Dr. Elizabeth Quackenbush appointed Chief Medical Officer

We are delighted to welcome Dr. Elizabeth Quackenbush as our Chief Medical Officer, strengthening our team at a pivotal moment in Ability’s journey.

Betsy is a physician scientist with over 20 years of leadership in drug development across preclinical discovery and late-stage clinical trials. She trained in Internal Medicine and Clinical Genetics at Beth Israel and Boston Children’s Hospital, followed by a fellowship at Dana-Farber Cancer Institute. Over her career, Elizabeth has held senior roles at Merck, Roche, Agennix, Celldex, and Elstar Therapeutics, with a focus on immuno-oncology, T-cell engagers, and gene therapies for rare diseases.

Her appointment marks an important milestone as Ability moves closer to the clinic. At Ability, we are advancing a pipeline of next-generation logic-gated antibody biotherapeutics powered by our AbiLeap^TM platform, designed to transform patient care in cancer and immunology. With Betsy’s expertise in translational medicine, we are well positioned to bring these innovations into the clinic and closer to patients.